Rescue Pacing for Congenital Complete Heart Block

Informazioni relative al progetto

RescuePace

ID dell’accordo di sovvenzione: 101081921

DOI

10.3030/101081921

Progetto chiuso

Data della firma CE 7 Luglio 2022

Data di avvio 1 Agosto 2022

Data di completamento 31 Gennaio 2024

Finanziato da

• European Research Council (ERC)

Costo totale

Nessun dato

Contributo UE

€ 150 000,00

Coordinato da

STICHTING AMSTERDAM UMC
Netherlands

Periodic Reporting for period 1 - RescuePace (Rescue Pacing for Congenital Complete Heart Block)

Periodo di rendicontazione: 2022-08-01 al 2024-01-31

Sintesi del contesto e degli obiettivi generali del progetto

To enable successful implementation of cardiac gene therapies it is of critical importance to develop improved gene transfer methods to target the heart and/or vascular system. In this project we therefore explored novel gene transfer method. Our initial efforts have been directed towards the field of gene therapy-based biological pacing. Our newly identified gene transfer methods are instrumental to the broader field of cardiovascular gene therapy.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

The experimental work that we performed focused on two vector system with high tropism for the heart, adenoviral vectors (AdV) and adeno associated viral vectors (AAV). For both vector systems we identified methods and/or new variants with high potential for translational development in the context of biological pacing and the broader field of cardiovascular gene therapy.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

We identified methods and/or new vector variants with high potential for translational development in the context of biological pacing and the broader field of cardiovascular gene therapy.